Published: March 2015 | Pages: 50 | Format: PDF and Online
This Competitive Intelligence Report about EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of solid tumors. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Table of Contents
2014 Sales of EGF-R Antibodies
Marketed EGF-R Antibodies
- Erbitux Sales & Pipeline
- Vectibix Sales & Pipeline
- Nimotuzumab Pipeline
EGF-R Antibody Biosuperiors
- Engineered EGF-R Antibodies
- Bi- and Multispecific EGF-R Antibodies
- EGF-R Antibody-Drug Conjugates
EGF-R Antibody Biosimilars
- Cetuximab Biosimilars
Corporate Biosuperior & Biosimilar EGF-R Antibody Pipelines